STOCK TITAN

Cibus, Inc. - CBUS STOCK NEWS

Welcome to our dedicated page for Cibus news (Ticker: CBUS), a resource for investors and traders seeking the latest updates and insights on Cibus stock.

Cibus, Inc. (Nasdaq: CBUS) is a pioneering biotechnology company that focuses on developing and commercializing proprietary gene-editing technologies. At the heart of Cibus’ innovation is its Rapid Trait Development System (RTDS®), a cutting-edge gene-editing platform that integrates crop-specific cell biology with advanced gene-editing techniques. The company's mission is to enhance plant traits to address crucial farming challenges related to productivity, disease resistance, and environmental sustainability.

One of Cibus’ key projects includes the development of herbicide tolerance traits in rice. The recent field trials for the HT1 and HT3 traits have shown promising results, meeting or exceeding performance expectations. This success has led to the first transfer of customer seeds containing these traits, marking a significant step in the company's commercial journey.

In addition, Cibus has made notable progress with its Pod Shatter Reduction (PSR) trait in canola. The PSR trait aims to minimize yield losses due to pod shattering, a common issue in canola farming. The successful field trials have enabled the transfer of PSR traits to multiple seed developers, with commercial hybrid sales expected as early as 2025.

Cibus is also at the forefront of legislative changes in Europe, supporting new regulations for New Genomic Techniques (NGTs) that classify certain gene-editing methods as ‘Conventional-like’. This regulatory recognition is expected to facilitate the commercial adoption of Cibus’ gene-edited traits across the European Union.

Recently, Cibus announced a strategic partnership with Loveland Products Inc. to commercialize herbicide tolerance traits in rice for the southern US market. This collaboration underscores Cibus’ commitment to providing innovative solutions to pressing agricultural challenges.

Cibus’ proprietary Trait Machine™ System is integral to its technology breakthrough. This system standardizes the gene-editing process, allowing precise modifications in a seed company’s elite germplasm without using foreign DNA or transgenes. The Trait Machine is currently operational for canola and rice, with broader applications anticipated in the future.

Overall, Cibus is revolutionizing plant breeding with its high-throughput gene-editing technology, addressing critical agricultural challenges, and paving the way for more sustainable and productive farming practices globally.

Rhea-AI Summary
Cibus, Inc. (Nasdaq: CBUS) announced its financial results for the quarter ended September 30, 2023, and provided a business update. The company completed extensive field trials for its PSR trait in canola and HT1 and HT3 in rice. It also reported continued progress of its high-throughput soybean editing system and two advanced traits for Sclerotinia resistance and HT2. Cibus launched strategic realignment and cost savings initiatives to focus on advancing late-stage activities. Initial UK field trials for its PSR trait in WOSR are underway, and the company is accelerating its PSR trait in the European market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.76%
Tags
-
Rhea-AI Summary
Cibus, Inc. supports the European Commission's proposal to regulate plants obtained from new genomic techniques (NGTs) and their food and feed. The proposed regulation introduces a 'Conventional-like' category for NGT products, aligning EU policy with trading partners in North and South America, Australia, and Japan. The report highlights the potential of NGTs to enhance agriculture and food production in Europe. Cibus' gene editing platform products, such as disease-resistant canola and oilseed rape with reduced seed losses, would fall under the 'Conventional-like' category.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.79%
Tags
none
-
Rhea-AI Summary
Cibus, Inc. (Nasdaq: CBUS) will report its third quarter 2023 financial results on November 9, 2023. The company's management team will host a conference call and webcast at 4:30 p.m. ET to discuss the financial results and other company updates. Interested individuals can access a dial-in replay of the call or a live audio webcast with accompanying slides on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.07%
Tags
conferences earnings
Rhea-AI Summary
Cibus announces election of Jim Collins, former CEO of Corteva, to its Board of Directors, bringing strategic vision and experience in gene editing and agriculture. Collins' insights and focus on commercialization can enhance Cibus' mission and potential.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.15%
Tags
management
-
Rhea-AI Summary
Cibus, Inc. to present at H.C. Wainwright 25th Annual Global Investment Conference on September 11-13, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.27%
Tags
conferences
-
Rhea-AI Summary
Cibus, Inc. announces financial results and business update, including progress in commercializing traits and opening a high-throughput breeding facility. Signs collaboration agreement with Bayer Ag. European Union proposes new regulations for gene editing techniques. Milestones achieved in 2023 and future milestones. Second quarter 2023 financial results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.76%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.33%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.33%
Tags
conferences earnings
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.33%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.89%
Tags
none

FAQ

What is the current stock price of Cibus (CBUS)?

The current stock price of Cibus (CBUS) is $2.645 as of December 20, 2024.

What is the market cap of Cibus (CBUS)?

The market cap of Cibus (CBUS) is approximately 73.8M.

What is the main focus of Cibus, Inc.?

Cibus, Inc. focuses on developing and commercializing gene-editing technologies to enhance plant traits, addressing productivity, disease resistance, and sustainability issues in farming.

What is the Rapid Trait Development System (RTDS®)?

RTDS® is Cibus’ proprietary gene-editing platform that integrates crop-specific cell biology with advanced gene-editing technologies to develop precise plant traits without using foreign DNA or transgenes.

What recent achievements has Cibus made in rice farming?

Cibus has successfully developed herbicide tolerance (HT1 and HT3) traits for rice, which have met or exceeded performance expectations in field trials and are now being transferred to seed developers for commercial use.

How is Cibus addressing the issue of pod shatter in canola?

Cibus has developed a Pod Shatter Reduction (PSR) trait for canola, which has shown positive field trial results and is being transferred to multiple seed developers, with commercial hybrid sales expected by 2025.

What recent legislative changes in Europe support Cibus’ technology?

The European Parliament recently voted in favor of new regulations for New Genomic Techniques (NGTs), classifying certain gene-editing methods as ‘Conventional-like’, facilitating the adoption of Cibus’ traits in the EU.

What is the Trait Machine™ System?

The Trait Machine™ System is Cibus’ standardized end-to-end gene-editing process that allows precise modifications in a seed company’s elite germplasm, ensuring the development of high-quality plant traits.

What is the significance of Cibus’ partnership with Loveland Products Inc.?

Cibus has partnered with Loveland Products to commercialize herbicide tolerance traits in rice, focusing on the southern US market to address weed management challenges.

How does Cibus plan to address Sclerotinia resistance in crops?

Cibus is developing multiple modes of action for Sclerotinia (White Mold) resistance in canola and other crops, with the goal of providing durable resistance and reducing crop losses.

Does Cibus use genetically modified organisms (GMOs) in its technology?

No, Cibus’ gene-editing technology does not use foreign DNA or transgenes, making its developed traits indistinguishable from those produced by conventional breeding.

What crops does Cibus focus on for its gene-editing technology?

Cibus focuses on major global row crops with large acreage such as canola, corn, rice, soybean, and wheat.

Cibus, Inc.

Nasdaq:CBUS

CBUS Rankings

CBUS Stock Data

73.81M
23.15M
24.24%
33.73%
7.39%
Biotechnology
Agricultural Chemicals
Link
United States of America
SAN DIEGO